1,764 Shares in Insulet Co. (NASDAQ:PODD) Acquired by Curbstone Financial Management Corp

Curbstone Financial Management Corp acquired a new position in Insulet Co. (NASDAQ:PODD) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 1,764 shares of the medical instruments supplier’s stock, valued at approximately $411,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in shares of Insulet by 1.1% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,265 shares of the medical instruments supplier’s stock valued at $1,264,000 after buying an additional 66 shares during the period. UMB Bank n.a. boosted its stake in shares of Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 81 shares during the period. Moody National Bank Trust Division boosted its stake in shares of Insulet by 2.6% during the 1st quarter. Moody National Bank Trust Division now owns 3,439 shares of the medical instruments supplier’s stock valued at $589,000 after buying an additional 87 shares during the period. Motley Fool Asset Management LLC boosted its stake in shares of Insulet by 7.1% during the 1st quarter. Motley Fool Asset Management LLC now owns 1,397 shares of the medical instruments supplier’s stock valued at $239,000 after buying an additional 93 shares during the period. Finally, Central Pacific Bank Trust Division boosted its stake in shares of Insulet by 23.2% during the 3rd quarter. Central Pacific Bank Trust Division now owns 505 shares of the medical instruments supplier’s stock valued at $118,000 after buying an additional 95 shares during the period.

Insulet Stock Performance

Shares of NASDAQ:PODD traded down $0.05 on Friday, hitting $229.94. 440,205 shares of the company were exchanged, compared to its average volume of 817,527. The firm has a market capitalization of $16.10 billion, a price-to-earnings ratio of 69.68, a PEG ratio of 4.34 and a beta of 1.21. The company’s 50 day moving average price is $209.88 and its two-hundred day moving average price is $192.02. Insulet Co. has a one year low of $125.82 and a one year high of $243.98. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.01). Insulet had a return on equity of 30.73% and a net margin of 21.11%. The business had revenue of $488.50 million during the quarter, compared to analyst estimates of $488.00 million. During the same period last year, the company earned $0.38 EPS. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. Research analysts expect that Insulet Co. will post 3.04 earnings per share for the current year.

Analyst Ratings Changes

PODD has been the subject of a number of research reports. Piper Sandler lifted their target price on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. BTIG Research reduced their price objective on shares of Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Canaccord Genuity Group lifted their price objective on shares of Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Citigroup lifted their price objective on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, OTR Global reaffirmed a “mixed” rating on shares of Insulet in a research note on Monday, June 10th. Four investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $234.60.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.